DMAC
Diamedica Therapeutics
$6.74
+$0.00 (+0.07%)Jul 27, 2026
Key metrics
The numbers that frame DMAC today
- Market cap
- $363.17M
- P/E (TTM)
- -10.3
- EV / FCF
- -11.6
- ROIC
- -90.4%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $4.01
- 52wk High
- $10.42
Growth
Revenue and earnings trend for DMAC
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about DMAC
Is Diamedica Therapeutics a good buy?
No. Diamedica Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Diamedica Therapeutics is selling at a very high price.
What is the market capitalization of DMAC?
Diamedica Therapeutics's market capitalization is $363.17M.
What is the P/E ratio for DMAC stock?
Diamedica Therapeutics's current P/E ratio is -10.3.
What is the 52-week high for DMAC stock?
The 52-week high for Diamedica Therapeutics is $10.42. The current close of $6.74 is 35.3% below that high.
What is the 52-week low for DMAC stock?
The 52-week low for Diamedica Therapeutics is $4.01. The current close of $6.74 is 67.9% above that low.
Does DMAC stock pay dividends?
Diamedica Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for DMAC?
Diamedica Therapeutics's Debt / Equity ratio is 0.